Phenotypic expression of swallowing function in Niemann-Pick disease type C1

Beth I Solomon, Andrea M Muñoz, Ninet Sinaii, Nicole M Farhat, Andrew C Smith, Simona Bianconi, An Dang Do, Michael C Backman, Leonza Machielse, Forbes D Porter, Beth I Solomon, Andrea M Muñoz, Ninet Sinaii, Nicole M Farhat, Andrew C Smith, Simona Bianconi, An Dang Do, Michael C Backman, Leonza Machielse, Forbes D Porter

Abstract

Background: Niemann-Pick disease type C1 (NPC1) is a rare autosomal recessive disease characterized by endolysosomal accumulation of unesterified cholesterol with progressive deterioration in swallowing, often leading to premature death. Although documented, the natural history of NPC1 swallowing dysfunction has yet to be delineated systematically. This manuscript aims to provide a comprehensive characterization of the phenotypic spectrum and progression of swallowing dysfunction in NPC1.

Methodology: The National Institutes of Health (NIH) NPC1 natural history study (NCT00344331) enrolled 120 patients, who underwent comprehensive interpretative swallow assessments for swallowing safety, dietary modifications, and aspiration risk. Longitudinal statistical modeling accounted for all outcomes with NPC1 disease covariates (first symptom onset, age at neurological symptom onset, seizure history, duration of neurological symptoms) as well as miglustat use (a glucosylceramide synthase inhibitor) and NIH study duration (NIHSD; the length of time an individual participated in the NIH study). Probabilities for disease progression and time to swallowing decline were conducted for the entire cohort.

Results: Time to swallowing decline with American Speech-Language-Hearing Association National Outcome Measure (ASHA-NOMS) and the NIH-adapted Penetration Aspiration Scale (NIH-PAS) were identified: [Formula: see text] person-years and [Formula: see text] person-years, respectively. NIHSD and seizure history consistently and significantly were associated with decline (ORNIHSD = 1.34-2.10, 95% CI 1.04-3.4, p = 0.001-0.026; ORSeizure = 3.26-18.22, 1.03-167.79; p = 0.001-0.046), while miglustat use revealed protection (ORMiglustat = 0.01-0.43, 0.007-0.98; p = 0.001-0.044). The probability of decline with NPC1 neurological severity scale and annual severity increment scale were established with the aforementioned covariates, varying amongst subgroups.

Conclusion: This study represents the most extensive collection of prospective, instrumental swallowing assessments in NPC1 to date with an interpretive analysis providing an improved understanding of NPC1 disease progression with swallowing function-serving as a foundation for clinical management and future NPC1 therapeutics.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT diagram of patient enrollment in National Institutes of Health Niemann–Pick disease Type C1 (NPC1) natural history study (NCT00344331)
Fig. 2
Fig. 2
Niemann–Pick disease Type C1 (NPC1) time to swallowing decline survival plots for the American Speech-Language-Hearing Association National Outcome Measures Scale (ASHA-NOMS) and the NIH-Adapted Rosenbek Penetration and Aspiration Scale (NIH-PAS)
Fig. 3
Fig. 3
Forest plots of longitudinal analysis results of all outcomes in patients with Niemann–Pick disease Type C1

References

    1. Wassif CA, Cross JL, Iben J, et al. High incidence of unrecognized visceral/neurological late-onset Niemann–Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med. 2016;18(1):41–48. doi: 10.1038/gim.2015.25.
    1. Ory DS. Niemann–Pick type C: a disorder of cellular cholesterol trafficking. Biochim Biophys Acta. 2000;1529(1–3):331–339. doi: 10.1016/s1388-1981(00)00158-x.
    1. Vanier MT. Niemann–Pick disease type C. Orphanet J Rare Dis. 2010;5:16. doi: 10.1186/1750-1172-5-16.
    1. Walterfang M, Chien YH, Imrie J, Rushton D, Schubiger D, Patterson MC. Dysphagia as a risk factor for mortality in Niemann–Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis. 2012;7:76. doi: 10.1186/1750-1172-7-76.
    1. Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996;11(2):93–98. doi: 10.1007/bf00417897.
    1. Ramsey D, Smithard D, Kalra L. Silent aspiration: What do we know? Dysphagia. 2005;20(3):218–225. doi: 10.1007/s00455-005-0018-9.
    1. Patterson MC, Garver WS, Giugliani R, et al. Long-term survival outcomes of patients with Niemann–Pick disease type C receiving miglustat treatment: a large retrospective observational study. J Inherit Metab Dis. 2020 doi: 10.1002/jimd.12245.
    1. Patterson MC, Mengel E, Wijburg FA, et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12. doi: 10.1186/1750-1172-8-12.
    1. Pineda M, Juríčková K, Karimzadeh P, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann–Pick disease Type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32. doi: 10.1186/s13023-019-0996-6.
    1. Yanjanin NM, Velez JI, Gropman A, et al. Linear clinical progression, independent of age of onset, in Niemann–Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(1):132–140. doi: 10.1002/ajmg.b.30969.
    1. Cortina-Borja M, Te Vruchte D, Mengel E, et al. Annual severity increment score as a tool for stratifying patients with Niemann–Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018;13(1):143. doi: 10.1186/s13023-018-0880-9.
    1. ASHA AS-L-HA. Dysarthria.
    1. Logemann JA. Evaluation and treatment of swallowing disorders. 2. Austin: PRO-ED; 1998. p. xiii, 406.
    1. Association AS-L-H. National outcomes measurement system: adults in healthcare-inpatient rehab national data report 2019. Rockville: National Center for Evidence-Based Practice in Communication Disorders; 2019.
    1. Senirli RT, Kuşçu O, Akyol U, et al. Otorhinolaryngological, audiovestibular and swallowing manifestations of patients with Niemann–Pick disease Type C. Int J Pediatr Otorhinolaryngol. 2016;80:1–4. doi: 10.1016/j.ijporl.2015.11.009.
    1. Lewis C, Keage M, Watanabe M, et al. Characterization of dysphagia and longitudinal changes in swallowing function in adults with Niemann–Pick disease type C treated with miglustat. Dysphagia. 2021;36(3):362–373. doi: 10.1007/s00455-020-10145-8.
    1. Thurm A, Chlebowski C, Joseph L, et al. Neurodevelopmental characterization of young children diagnosed with Niemann–Pick disease, type C1. J Dev Behav Pediatr. 2020;41(5):388–396. doi: 10.1097/dbp.0000000000000785.
    1. Boyle BR, Melli SE, Altreche RS, et al. NPC1 deficiency impairs cerebellar postnatal development of microglia and climbing fiber refinement in a mouse model of Niemann–Pick disease type C. Development. 2020 doi: 10.1242/dev.189019.
    1. Palmer JB, Hiiemae KM, Matsuo K, Haishima H. Volitional control of food transport and bolus formation during feeding. Physiol Behav. 2007;91(1):66–70. doi: 10.1016/j.physbeh.2007.01.018.
    1. Palmer JB, Rudin NJ, Lara G, Crompton AW. Coordination of mastication and swallowing. Dysphagia. 1992;7(4):187–200. doi: 10.1007/bf02493469.
    1. Leder SB, Suiter DM, Lisitano Warner H. Answering orientation questions and following single-step verbal commands: effect on aspiration status. Dysphagia. 2009;24(3):290–295. doi: 10.1007/s00455-008-9204-x.
    1. Jestrović I, Coyle JL, Perera S, Sejdić E. Influence of attention and bolus volume on brain organization during swallowing. Brain Struct Funct. 2018;223(2):955–964. doi: 10.1007/s00429-017-1535-7.
    1. Solomon BI, Smith AC, Sinaii N, et al. Association of miglustat with swallowing outcomes in Niemann–Pick disease, type C1. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.3241.
    1. Stein VM, Crooks A, Ding W, et al. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann–Pick disease type C. J Neuropathol Exp Neurol. 2012;71(5):434–448. doi: 10.1097/NEN.0b013e31825414a6.
    1. Patterson MC, Lloyd-Price L, Guldberg C, et al. Validation of the 5-domain Niemann–Pick type C clinical severity scale. Orphanet J Rare Dis. 2021;16(1):79. doi: 10.1186/s13023-021-01719-2.
    1. Evans W, Patterson M, Platt F, Guldberg C, Mathieson T, Pacey J. International consensus on clinical severity scale use in evaluating Niemann–Pick disease type C in paediatric and adult patients: results from a Delphi Study. Orphanet J Rare Dis. 2021;16(1):482. doi: 10.1186/s13023-021-02115-6.
    1. Farhat N, Bailey L, Friedmann K, et al. Consistently high agreement between independent raters of Niemann–Pick type C1 clinical severity scale in phase 2/3 trial. Pediatr Neurol. 2021 doi: 10.1016/j.pediatrneurol.2021.11.009.
    1. Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann–Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50. doi: 10.1186/s13023-018-0785-7.
    1. Pineda M, Jurickova K, Karimzadeh P, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann–Pick disease Type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32. doi: 10.1186/s13023-019-0996-6.
    1. Pineda M, Jurickova K, Karimzadeh P, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32. 10.1186/s13023-019-0996-6.
    1. Patterson MC, Mengel E, Vanier MT, Moneuse P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry. Orphanet J Rare Dis. 2020;15(1):104. 10.1186/s13023-020-01363-2.
    1. Patterson MC, Mengel E, Vanier MT, Moneuse P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann–Pick disease type C: a final report of the NPC registry. Orphanet J Rare Dis. 2020;15(1):104. doi: 10.1186/s13023-020-01363-2.
    1. Patterson MC, Lloyd-Price L, Guldberg C, et al. Validation of the 5-domain Niemann-Pick type C clinical severity scale. Orphanet J Rare Dis. 2021;16(1):79. 10.1186/s13023-021-01719-2.
    1. Evans W, Patterson M, Platt F, Guldberg C, Mathieson T, Pacey J. International consensus on clinical severity scale use in evaluating Niemann-Pick disease Type C in paediatric and adult patients: results from a Delphi Study. Orphanet J Rare Dis. 2021;16(1):482. 10.1186/s13023-021-02115-6.
    1. Farhat N, Bailey L, Friedmann K, et al. Consistently high agreement between independent raters of Niemann-Pick type C1 clinical severity scale in phase 2/3 trial. Pediatr Neurol. 2022;127:32–38. 10.1016/j.pediatrneurol.2021.11.009.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner